Clinical trial
Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma…
NCT00406978 · Silvio Aime, Other · Completed
Key facts
| NCT number | NCT00406978 |
|---|---|
| Title | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients |
| Official title | A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients |
| Acronym | MPTD |
| Lead sponsor | Silvio Aime, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Prednisone, Melphalan, Thalidomide, Defibrotide |
| Enrollment | 24 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2010 |
| Completion | Apr 1, 2014 |
| First posted | Dec 4, 2006 |
| Last update posted | May 10, 2016 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: